Founded in 2022, Hangzhou Sanjing Biotechnology Co., Ltd. focuses on nanobody R&D and services, providing nanobodies and early-discovery CRO services to innovative drug developers.
The company runs a complete nanobody discovery platform focused on early discovery, feeding source innovation into clients' drug programmes. More than one hundred popular targets have been validated, with partnerships across pharmaceutical R&D companies and multiple early-stage nanobody projects delivered.
SanjingBio operates high-standard modern laboratories and an advanced instrument platform under a strict quality-control system. Our R&D team, led by PhDs from Zhejiang University, has spent years in nanobodies and recombinant proteins, and works with leading universities to keep pushing the technology forward. With excellent quality, fast delivery and flexible partnership models, we power new-drug R&D and accelerate the translation of innovation.
of Team Experience
Monthly Protein Expression Projects
Validated Drug Targets
Target Proteins In Stock
High-standard modern biology laboratories and an advanced instrument platform, run under a strict quality-control system.
Functional Lab Zones ×8
Biology lab · Cell culture room · ELISA assays · Western blot · IHC assays · IF assays · Prokaryotic expression · Cell-based assays
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
